ANDA 202599, held by Eugia Pharma. Ondansetron Hydrochloride.
As of Nov 16, 2026, ANDA 202599 (Ondansetron Hydrochloride), held by Eugia Pharma, was first approved by FDA on Dec 21, 2012, with 5 approved supplements and 0 published complete response letters.
Ondansetron Injection is a 5-HT 3 receptor antagonist indicated for the prevention of: nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. postoperative nausea and/or vomiting. 1.1 Prevention of Nausea and Vomiting Associated with Initial and Repeat Courses of Emetogenic Cancer Chemotherapy Ondansetron Injection is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin. Ondansetron Injection is approved for patients aged 6 months and older. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 21, 2012 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ondansetron HydrochlorideEQ 2MG BASE/ML · injectable;injection | Ondansetron Hydrochloride | Discontinued |
| Mar 1, 2022 | Supplement 9Labeling · Standard review | Approved | None posted |
| Aug 19, 2021 | Supplement 6Labeling · Standard review | Approved | None posted |
| Aug 19, 2021 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jan 17, 2015 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jan 17, 2015 | Supplement 5Labeling · Standard review | Approved | None posted |
| Dec 21, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters